01 — At a Glance
The Eye Specialist Nobody Knew Was Printing Money
- 52-Week High / Low₹6,392 / ₹3,750
- Q3 FY26 Sales₹116 Cr
- Q3 FY26 PAT₹17.3 Cr
- Annualised EPS₹35.76
- TTM EPS₹146
- Book Value / Share₹651
- Price to Book7.19x
- OPM (Q3)30%
- Total Facilities63 (AEHL)
- Surgeries Performed (FY25)62,000
Flash Summary: AEHL just posted Q3 PAT of ₹17.3 crore — up 66% YoY. Revenue grew 22%, earnings grew 66%. That gap is your Mojo Meter. The stock trades at 32.4x P/E with 29.5% ROE and a P/BV of 7.2x. The market says: “Beta hai lekin quality hai.” Your auditor says: “Beta? Yeh sab risk hai.” Somewhere in between is the truth.
02 — Introduction
The Eye Hospital That Learned to Print Cash While Others Counted Glasses
Let me paint you a picture. In 1994, Dr. Agarwal decided the Indian eye-care space needed an organized player. Spectacles were selling at street corners. Cataract surgeries happened in mohalla clinics where the surgeon’s definition of “sterile” was “we dusted it yesterday.”
Thirty years later, Dr. Agarwal’s Health Care Limited (AHCL) has become India’s largest eye-care services chain by revenue. The parent company. The boss. The one that went public in February 2025 and raised ₹300 crore like it was picking up spare change from the sofa.
Dr. Agarwal’s Eye Hospital Limited (AEHL) is the subsidiary. 63 facilities in Tamil Nadu and beyond. 230 doctors. 588,000 patients served in FY25. 62,000 surgeries. It’s the surgical wing — the money printer of the group. And now, the boards have decided: why have two listed entities when you can have one mega-entity printing money twice as fast?
The Q3 FY26 story has exactly three chapters. First: yet another quarter where PAT grew 66% while revenue grew 22%. (Translation: margins are expanding like a balloon in summer.) Second: the company announced it’s merging with its parent, AHCL. Subject to NCLT approval. Subject to shareholder approval. Subject to three more government approvals you’ve never heard of. Third: everyone’s wondering what the merger means. Accretion? Dilution? Will the queue in the doctor’s office get longer?
Merger Snapshot (Announced Aug 2025): For every 2 shares of AEHL you own, you’ll get 23 shares of AHCL. That’s a 15% premium to the 10-day VWAP. AHCL is also buying ₹70 crore worth of new AEHL shares at ₹5,270 per share for capex. Timeline: Merger expected by Q2 FY27 if all gods are appeased and all stamps are collected.
03 — Business Model: WTF Do They Even Do?
They Fix Eyes. And Apparently, That’s a Goldmine.
AEHL operates 63 eye-care facilities across Tamil Nadu, Andhra Pradesh, Kerala, Rajasthan, and a few other states. The hub-and-spoke model is genius: primary centres (71) are basic consultation centers. Secondary centres (149) do surgical procedures. Tertiary centres (29) — the jewels — include three “Centres of Excellence” where complex surgeries happen.
Revenue breakdown in FY25: Surgeries = 63.9%. Opticals, contact lenses, pharma = 23.2%. Consultations and other stuff = 12.8%. Cash patients dominate payor mix at 72.9%. Insurance at 23.1%. Government at 4%. This is important because cash patients = zero collection delays = better working capital.
Cataract surgery is the bread-and-butter. It’s simple, it’s repeatable, margins are fat, and India has 400 million eyeballs that haven’t had cataracts removed yet. AEHL is also doing refractive surgeries (SMILE, FEMTO Cataract), retinal surgeries, corneal grafts — basically everything that doesn’t require removing the entire eye.
The facilities are asset-light. They lease the spaces. Fixed costs are controlled. When a new centre breaks even, it’s gravy. This model explains the 30% OPM and the 66% PAT growth despite 22% revenue growth. Operational leverage is like espresso shots — small volume, huge kick.
Surgery Revenue63.9%of total
Cash Patients72.9%payor mix
OPM (Q3)30%operating margin
Facility Growth2.4xsince FY22
Fun fact: In FY25, AEHL performed 62,000 surgeries with 230 doctors. That’s 270 surgeries per doctor per year, or one per doctor per day-and-a-half. If you’re scared of eye surgery, know that your surgeon’s scalpel has seen more eyeballs this year than most people see in a lifetime. Comfort level: zero. Competence level: through the roof.
04 — Financials Overview
Q3 FY26: The Earnings Engine That Never Idles
Result type: Quarterly Results | Q3 FY26 EPS: ₹35.76 | Calculated as (10.77 + 29.11 + 35.76)/3 × 4 = ₹35.76 annualised | TTM EPS: ₹146
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 116 | 95 | 118 | +22.2% | -1.8% |
| Operating Profit | 34 | 26 | 40 | +26.5% | -14% |
| OPM % | 29.3% | 27.4% | 33.9% | +190 bps | -460 bps |
| PAT | 17.3 | 10.4 | 19.3 | +66.2% | -10% |
| EPS (₹) | 35.76 | 21.6 | 40.1 | +65.5% | -10.9% |
The Gap Story: Revenue +22%, PAT +66%. That 44-percentage-point gap is not magic. It’s operational leverage. Every incremental rupee of revenue hits EBITDA at higher margins because you’re not hiring proportional costs. The operating margin expanded 190 bps YoY to 29.3%. Now, Q3 to Q2 was a blip — seasonality or project completions. But the YoY trajectory is the real story.
💬 With 29.5% ROE and 66% earnings growth, why is AEHL trading at 32.4x P/E while peers in healthcare trade at 40-60x? Is the market discounting merger risk, or is there something else the data doesn’t show? Your thoughts?
05 — Valuation Discussion: Fair Value Range
Is AEHL Expensive? Let’s Do the Math.
